Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib

被引：5

作者：

Wang, L

Butt, NM

Atherton, MG

Clark, RE

机构：

[1] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England

[2] Liverpool Womens Hosp, Merseyside & Cheshire Cytogenet Lab, Liverpool L8 7SS, Merseyside, England

来源：

LEUKEMIA | 2004年 / 18卷 / 05期

关键词：

D O I：

10.1038/sj.leu.2403342

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1025 / 1027

页数：4

共 13 条

[1] Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients [J].

Auffermann-Gretzinger, S ;

Lossos, IS ;

Vayntrub, TA ;

Leong, W ;

Grumet, FC ;

Blume, KG ;

Stockerl-Goldstein, KE ;

Levy, R ;

Shizuru, JA .

BLOOD, 2002, 99 (04) :1442-1448

[2] Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia [J].

Choudhury, A ;

Gajewski, JL ;

Liang, JC ;

Popat, U ;

Claxton, DF ;

Kliche, KO ;

Andreeff, M ;

Champlin, RE .

BLOOD, 1997, 89 (04) :1133-1142

[3] Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [J].

Clark, RE ;

Dodi, IA ;

Hill, SC ;

Lill, JR ;

Aubert, G ;

Macintyre, AR ;

Rojas, J ;

Bourdon, A ;

Bonner, PLR ;

Wang, LH ;

Christmas, SE ;

Travers, PJ ;

Creaser, CS ;

Rees, RC ;

Madrigal, JA .

BLOOD, 2001, 98 (10) :2887-2893

[4] Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells [J].

Dietz, AB ;

Bulur, PA ;

Erickson, MR ;

Wettstein, PJ ;

Litzow, MR ;

Wyatt, WA ;

Dewald, GW ;

Tefferi, A ;

Pankratz, VS ;

Vuk-Pavlovic, S .

JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (01) :95-101

[5] Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration [J].

Dong, R ;

Cwynarski, K ;

Entwistle, A ;

Marelli-Berg, F ;

Dazzi, F ;

Simpson, E ;

Goldman, JM ;

Melo, JV ;

Lechler, RI ;

Bellantuono, I ;

Ridley, A ;

Lombardi, G .

BLOOD, 2003, 101 (09) :3560-3567

[6]

Eibl B, 1997, GENE CHROMOSOME CANC, V20, P215, DOI 10.1002/(SICI)1098-2264(199711)20:3<215::AID-GCC1>3.0.CO

[7]

2-5

[8] Alloreactive CD4(+) T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen [J].

Jiang, YZ ;

Mavroudis, D ;

Dermime, S ;

Hensel, N ;

Couriel, D ;

Molldrem, J ;

Barrett, AJ .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (03) :606-612

[9]

MOHTY M, 2004, BLOOD 0108

[10] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

← 1 2 →